TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03742986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 360mg
Description: Nivolumab 360 mg IV on Day 1 of every 21 day cycle (Cycle 1-4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 360mg
Description: Nivolumab 360 mg IV on Day 1 of every 21 day cycle (Cycle 1-4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel 80mg/m^2
Description: Paclitaxel 80mg/m\^2 IV on Day of 1, 8, 15 of every 21 day cycle (Cycle 1-4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin 60mg/m^2
Description: Doxorubicin 60 mg/m\^2 IV on Day 1 of every 14 day cycle (Cycle 5-8)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin 60mg/m^2
Description: Doxorubicin 60 mg/m\^2 IV on Day 1 of every 14 day cycle (Cycle 5-8)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 600mg/m^2
Description: Cyclophosphamide 600mg/m\^2 on Day 1 of every 14 day cycle (Cycle 5-8)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 600mg/m^2
Description: Cyclophosphamide 600mg/m\^2 on Day 1 of every 14 day cycle (Cycle 5-8)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel 80mg/m^2 or Docetaxel 75mg/m^2
Description: Paclitaxel 80mg/m\^2 on Day 1, 8, 15 of every 21 day cycle (Cycle 1-4) OR Docetaxel 75mg/m\^2 on Day 1 of every 21 day cycle (Cycle 1-4)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab 8mg/kg and 6 mg/kg
Description: Trastuzumab 8mg/kg IV on Day 1 of Cycle 1 and then 6mg/kg IV on Day 1 of Cycle 2-4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab 840mg and 420mg
Description: Pertuzumab 840mg on Day 1 of Cycle 1 and then 420mg IV on Day 1 of Cycle 2-4
Study: NCT03216707

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HD tDCS active motor cortex
Description: the intervention will be 10 participants will be subjected to 1.5-gram of Capsaicin cream 0.075 concentration for 30 min then participants will be subjected to active stimulation targeting motor cortex area with the high-definition transcranial direct current stimulation device with current intensity 2 milliampere for 20 min

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HD tDCS active insula cortex
Description: the intervention will be 10 participants will be subjected to 1.5 gram of Capsaicin cream 0.075 concentration for 30 min then participants will be subjected to active stimulation targeting Insular cortex area with the high-definition transcranial direct current stimulation device, with current intensity 2milliampere for 20 min

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: HD tDCS sham motor cortex
Description: the intervention 10 participants will be subjected to1.5 gram of Capsaicin cream 0.075% concentration for 30 min then participants will be subjected to sham stimulation targeting motor cortex area using the high-definition transcranial direct current stimulation device by starting stimulation for 30 seconds then stop stimulation for 20 min

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin cream
Description: Capsaicin cream

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin cream
Description: Capsaicin cream

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Capsaicin cream
Description: Capsaicin cream
Study: NCT02879955

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose + Fructose
Description: Ingestion of the separate monosaccharides glucose (25 g) and fructose (25 g) dissolved in 200 mL of water. The load provides 0.1385 mol glucose and 0.1385 mol fructose.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose + Fructose
Description: Ingestion of the separate monosaccharides glucose (25 g) and fructose (25 g) dissolved in 200 mL of water. The load provides 0.1385 mol glucose and 0.1385 mol fructose.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: Ingestion of the disaccharide sucrose (47.5 g) dissolved in 200 mL of water. The load provides 0.1385 mol glucose and 0.1385 mol fructose.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: Ingestion of the disaccharide sucrose (47.5 g) dissolved in 200 mL of water. The load provides 0.1385 mol glucose and 0.1385 mol fructose.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isomaltulose
Description: Ingestion of the slowly digestable disaccharide isomaltulose (47.5 g) dissolved in 200 mL of water. The load provides 0.1385 mol glucose and 0.1385 mol fructose.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isomaltulose
Description: Ingestion of the slowly digestable disaccharide isomaltulose (47.5 g) dissolved in 200 mL of water. The load provides 0.1385 mol glucose and 0.1385 mol fructose.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose + Acarbose
Description: Ingestion of the disaccharide sucrose (47.5 g) and the alpha glucosidase inhibitor acarbose dissolved in 200 mL of water. The load provides 0.1385 mol glucose and 0.1385 mol fructose.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose + Acarbose
Description: Ingestion of the disaccharide sucrose (47.5 g) and the alpha glucosidase inhibitor acarbose dissolved in 200 mL of water. The load provides 0.1385 mol glucose and 0.1385 mol fructose.
Study: NCT03249428

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Improved Quality of Life of low-income Canadians that smoke tobacco and other substances
Description: Assess effectiveness, safety and tolerability of electronic-cigarettes (e-cigs) with nicotine or Nicotine Replacement Therapy (NRT) with individual counseling for tobacco cessation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Improved Quality of Life of low-income Canadians that smoke tobacco and other substances
Description: Assess effectiveness, safety and tolerability of electronic-cigarettes (e-cigs) with nicotine or Nicotine Replacement Therapy (NRT) with individual counseling for tobacco cessation.
Study: NCT04951908

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MRI of TMJ

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MRI of TMJ
Study: NCT00872521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAD induction
Description: Open Label Treatment:~Four 21-day Treatment Cycles Bortezomib 1.3 mg/m2 i.v. (D1, 4, 8 \& 11), Doxorubicin 20 mg/m2 i.v. (D1 \& 4), Dexamethasone 20 mg p.o. (D1, 2, 4, 5, 8 , 9, 11 \& 12)
Study: NCT03744637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5475
Description: Single inhaled dose of MK-5475 120, 165, 240, 300, 360, or 480 ug depending upon randomization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5475
Description: Single inhaled dose of MK-5475 120, 165, 240, 300, 360, or 480 ug depending upon randomization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5475
Description: Single inhaled dose of MK-5475 120, 165, 240, 300, 360, or 480 ug depending upon randomization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5475
Description: Single inhaled dose of MK-5475 120, 165, 240, 300, 360, or 480 ug depending upon randomization

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single inhaled dose of placebo to match MK-5475
Study: NCT00235573

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: After taking a fasting blood sample, all subjects were given a light breakfast plus 9 micrograms of vitamin B12. Two more doses of vitamin B12, 9 micrograms each, were administered 6 hours apart.
Study: NCT05618015

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supervised progressive resistance training
Description: Exercises were performed with cable resistance training machine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Home-based progressive resistance training
Description: In the first session, with the help of a physiotherapist, strengthening exercises were shown and taught to the patients. Two weeks after the beginning of the home-based PRT program, patients were called to check whether they were doing the exercises in the home program correctly. After the checking for exercise training, the patients were called by phone every two weeks for follow-up.
Study: NCT02975180

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FES
Description: The MyndMove FES System (MyndTec Inc., Mississauga, ON) is a fully programmable FES device with eight channels. This system allows motor practice of 17 different reaching and grasping protocols. The muscles stimulated may include the anterior, middle and posterior deltoid, biceps and triceps brachii, flexor digitorum superficialis and profundus, extensor digitorum, thenar eminence, lumbricals, and interossei. The sophistication of this system is unique. In contrast, many of the MyndMove stimulation protocols involve activation of small muscles that are used for fine motor control. The second FES device that will be used is the Odstock 2-channel Stimulator (FES Mobility Ltd., Vancouver, BC). While less sophisticated than the MyndMove system, it is smaller and more portable.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional
Description: Conventional training involves repetitive practice of upper extremity movements with manual assistance provided by a therapist as needed.
Study: NCT04653831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Treatment with Pirfenidone as mentioned in the experimental arm description.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: Treatment with SoC as mentioned in the control arm description.
Study: NCT02768168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dezocine
Description: receive dezocine 0.1 mg/kg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: receive matching placebo (equal volume of normal saline)
Study: NCT01101750

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Quadrivalent HPV for types 6, 11, 16 and 18
Description: Per standard of care, Gardasil 0.5ml IM injection on day one, month 2, and month 6.~Serum samples on day one, month 3 and month 7.
Study: NCT04986241

Intervention type: DRUG
Intervention: Statin
Description: Chronic use of statin prescribed previously by the assistant physician.

Intervention type: DRUG
Intervention: Statin
Description: Chronic use of statin prescribed previously by the assistant physician.

Intervention type: DRUG
Intervention: Statin
Description: Chronic use of statin prescribed previously by the assistant physician.

Intervention type: DRUG
Intervention: Statin
Description: Chronic use of statin prescribed previously by the assistant physician.

Intervention type: OTHER
Intervention: Physical activity
Description: Physically active participants

Intervention type: OTHER
Intervention: Physical activity
Description: Physically active participants

Intervention type: OTHER
Intervention: Physical activity
Description: Physically active participants

Intervention type: OTHER
Intervention: Physical activity
Description: Physically active participants

Intervention type: OTHER
Intervention: Sedentary
Description: Physically inactive or sedentary participants.

Intervention type: OTHER
Intervention: Sedentary
Description: Physically inactive or sedentary participants.

Intervention type: OTHER
Intervention: Sedentary
Description: Physically inactive or sedentary participants.

Intervention type: OTHER
Intervention: Sedentary
Description: Physically inactive or sedentary participants.
Study: NCT02595502

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: JJVC Marketed Contact Lens (Test)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: JJVC Marketed Contact Lens (Test)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Competitor Marketed Contact Lens (Control)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Competitor Marketed Contact Lens (Control)
Study: NCT03193632

Intervention type: DIAGNOSTIC_TEST
Intervention: US Muscle layer thickness (MLT) estimation
Description: Three measurements will be made at each of three sites; mid-upper arm, forearm and thigh anteriorly and the mean value will be calculated. Measurement sites will be marked with indelible ink to ensure day-to-day consistency.~1. Thigh: MLT of the quadriceps femoris muscle (M. Vastus intermedius and M. rectus femoris) will be assessed bilaterally~2. Mid-upper arm: Muscle layer thickness will be measured over the biceps,midway between the tip of the acromion and the tip of the olecranon~3. Forearm: A point midway between the antecubital skin crease and the ulnar styloid was marked and muscle thickness down to the interosseus membrane

Intervention type: DIAGNOSTIC_TEST
Intervention: REE estimation by indirect calorimetry
Description: REE will be calculated using indirect calorimetry via metabolic module on General Electric ventilator (Engstrom Carestation and Carescape R860, GE Health care, USA) All indirect calorimetric measurements will be done using standardized technique. Gas calibration will be performed before each measurement, and the measurements will last for at least 30 minutes. Measurements will be taken with the patient lying supine and ventilator settings left unchanged for at least 60 minutes ahead of indirect calorimetry. The REE will be calculated during the first 24 hours of admission to ICU.
Study: NCT02727738

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Selenium
Description: Selenium 80 mg bid for 90 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methimazole
Description: Methimazole starting dose depending on FT3 values (15 mg/day or 20 mg/day or 30 mg/day, for FT3 values \<10 pg/ml, 10-15 pg/ml, \>15 pg/ml, respectively) to be tapered by 5 mg/day every 15 days down to values sufficient for FT3 to be normal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methimazole
Description: Methimazole starting dose depending on FT3 values (15 mg/day or 20 mg/day or 30 mg/day, for FT3 values \<10 pg/ml, 10-15 pg/ml, \>15 pg/ml, respectively) to be tapered by 5 mg/day every 15 days down to values sufficient for FT3 to be normal
Study: NCT01493050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevelamer Carbonate
Description: 1600 mg (two 800 mg in the form of tablets or powder to be diluted in water) TID with meals for 26 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: calcium carbonate
Description: 1200 mg of calcium carbonate TID with meals for 26 weeks
Study: NCT02896764

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cone-beam CT
Study: NCT02311374

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Brain connectivity and physiology
Description: Two MRI scanning session will be obtained for each participant both at the same time of day (9AM 12 PM). In one occasion they will be scanned after a night of rested sleep while awake and on another day they will be scanned after one night of sleep deprivation while sleeping in the scanner. In addition to the most sensitive technique selected in the development phase (either DWI or MT), each imaging MRI session will include (1) a resting-state functional connectivity (RSFC; 10 minutes) scan using single-shot T2\*-weighted EPI; and (2) quantitative T1 relaxometry (T1) in a CSF voxel (1mL; cubic) using an inversion recovery experiment with increased interpulse intervals (TI = 200, 300, 400, 500, 700, 1000, 1500, 2000, 3000, 5000, 10000 ms) and a long TR (10000 ms; scan time 2 min) to assess the level of solutes in CSF.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Brain connectivity and physiology
Description: Two MRI scanning session will be obtained for each participant both at the same time of day (9AM 12 PM). In one occasion they will be scanned after a night of rested sleep while awake and on another day they will be scanned after one night of sleep deprivation while sleeping in the scanner. In addition to the most sensitive technique selected in the development phase (either DWI or MT), each imaging MRI session will include (1) a resting-state functional connectivity (RSFC; 10 minutes) scan using single-shot T2\*-weighted EPI; and (2) quantitative T1 relaxometry (T1) in a CSF voxel (1mL; cubic) using an inversion recovery experiment with increased interpulse intervals (TI = 200, 300, 400, 500, 700, 1000, 1500, 2000, 3000, 5000, 10000 ms) and a long TR (10000 ms; scan time 2 min) to assess the level of solutes in CSF.
Study: NCT03436017

Intervention type: OTHER
Intervention: Metabolomic approach
Description: Biological samples (blood and urine) for a multimodal metabolomic approach

Intervention type: OTHER
Intervention: Metabolomic approach
Description: Biological samples (blood and urine) for a multimodal metabolomic approach
Study: NCT04435808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine- oral administration: Duration: up to 90 days or until meeting study termination criteria. Subjects will recieve 600 mg loading dose, followed by 200 mg daily (tablets).~Loading dose: 600 mg once for the first day Maintenance dose: 200 mg, daily
Study: NCT02311374

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Brain Wave
Description: ECG will be used to monitor heart rate variability (HRV), which differ significantly between the waking state and the different sleep stages

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Brain Wave
Description: ECG will be used to monitor heart rate variability (HRV), which differ significantly between the waking state and the different sleep stages
Study: NCT03835754

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCS Heart System
Description: The OCS Heart System preserves the heart in a near-physiological, beating state by perfusing the heart with a warmed, donor-blood based perfusate that is supplemented with nutrients and oxygen in a controlled and protected environment
Study: NCT04477629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: Belatacept will be given in the following way - 10mg/kg IV day 1, 5, end of weeks 2, 4, 8, 12 then 5mg/kg every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Non-experimental: Tacrolimus will be given in the following way - trough level at month 1, 10-12ng/mL; month 2-3, 6-10ng/mL; month 4-6, 4-6ng/mL; months 7-9 taper off.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Non-experimental: MMF is part of standard of care after heart transplant and will follow dosing recommendations as per standard clinical practice at 500-1500mg twice a day (BID) (dosed to tolerance and effect).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Description: Non-experimental: CS is part of standard of care after heart transplant and will follow dosing recommendations as per standard clinical practice at a dose no less than 5mg/d.
Study: NCT00310180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy or partial breast irradiation

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo radiation therapy or partial breast irradiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy or partial breast irradiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen Citrate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen Citrate
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen Citrate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen Citrate
Description: Given PO
Study: NCT03697304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754091
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754091
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754091
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754091
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754091
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754091
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754091
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754091
Description: Solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754111
Description: Solution for infusion